Endpoints News 生物医药· Elizabeth Cairns·· 23 天前AI 评分50
礼来 triple-G 药物 retatrutide 在糖尿病对比中表现优于诺和诺德 Ozempic
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
AI 导读
Endpoints News 报道称,礼来的 triple-G 药物 retatrutide 在糖尿病相关对比中表现优于诺和诺德的 Ozempic,该比较基于跨试验数据。原文为付费内容,未披露具体疗效数据、试验名称与期别。
正文
Eli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news